1
|
Tapia-González A, Vélez-Ixta JM, Bueno-Hernández N, Piña-Escobedo A, Briones-Garduño JC, de la Rosa-Ruiz L, Aguayo-Guerrero J, Mendoza-Martínez VM, Snowball-del-Pilar L, Escobedo G, Meléndez-Mier G, Méndez-García LA, García-Mena J, Esquivel-Velázquez M. Maternal Consumption of Non-Nutritive Sweeteners during Pregnancy Is Associated with Alterations in the Colostrum Microbiota. Nutrients 2023; 15:4928. [PMID: 38068786 PMCID: PMC10708104 DOI: 10.3390/nu15234928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 11/11/2023] [Accepted: 11/24/2023] [Indexed: 12/18/2023] Open
Abstract
Non-nutritive sweeteners (NNSs) provide a sweet taste to foods and beverages without significantly adding calories. Still, their consumption has been linked to modifications in adult's and children's gut microbiota and the disruption of blood glucose control. Human milk microbiota are paramount in establishing infants' gut microbiota, but very little is known about whether the consumption of sweeteners can alter it. To address this question, we sequenced DNA extracted colostrum samples from a group of mothers, who had different levels of NNS consumption, using the Ion Torrent Platform. Our results show that the "core" of colostrum microbiota, composed of the genera Bifidobacterium, Blautia, Cutibacteium, Staphylococcus, and Streptococcus, remains practically unchanged with the consumption of NNS during pregnancy, but specific genera display significant alterations, such as Staphylococcus and Streptococcus. A significant increase in the unclassified archaea Methanobrevibacter spp. was observed as the consumption frequency of NNS increased. The increase in the abundance of this archaea has been previously linked to obesity in Mexican children. NNS consumption during pregnancy could be related to changes in colostrum microbiota and may affect infants' gut microbiota seeding and their future health.
Collapse
Affiliation(s)
- Alejandro Tapia-González
- Laboratorio de Proteómica e Inmunometabolismo, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (A.T.-G.); (N.B.-H.); (L.S.-d.-P.); (G.E.); (L.A.M.-G.)
| | - Juan Manuel Vélez-Ixta
- Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City 07360, Mexico; (J.M.V.-I.); (A.P.-E.)
| | - Nallely Bueno-Hernández
- Laboratorio de Proteómica e Inmunometabolismo, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (A.T.-G.); (N.B.-H.); (L.S.-d.-P.); (G.E.); (L.A.M.-G.)
| | - Alberto Piña-Escobedo
- Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City 07360, Mexico; (J.M.V.-I.); (A.P.-E.)
| | | | - Leticia de la Rosa-Ruiz
- Banco de Leche Humana y Lactancia, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico
| | - José Aguayo-Guerrero
- Laboratorio de Proteómica e Inmunometabolismo, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (A.T.-G.); (N.B.-H.); (L.S.-d.-P.); (G.E.); (L.A.M.-G.)
| | - Viridiana M. Mendoza-Martínez
- Laboratorio de Proteómica e Inmunometabolismo, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (A.T.-G.); (N.B.-H.); (L.S.-d.-P.); (G.E.); (L.A.M.-G.)
| | - Lenin Snowball-del-Pilar
- Laboratorio de Proteómica e Inmunometabolismo, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (A.T.-G.); (N.B.-H.); (L.S.-d.-P.); (G.E.); (L.A.M.-G.)
| | - Galileo Escobedo
- Laboratorio de Proteómica e Inmunometabolismo, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (A.T.-G.); (N.B.-H.); (L.S.-d.-P.); (G.E.); (L.A.M.-G.)
| | - Guillermo Meléndez-Mier
- Facultad de Salud Pública y Nutrición, Universidad Autónoma de Monterrey, Monterrey 64460, Mexico;
| | - Lucía A. Méndez-García
- Laboratorio de Proteómica e Inmunometabolismo, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (A.T.-G.); (N.B.-H.); (L.S.-d.-P.); (G.E.); (L.A.M.-G.)
| | - Jaime García-Mena
- Departamento de Genética y Biología Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City 07360, Mexico; (J.M.V.-I.); (A.P.-E.)
| | - Marcela Esquivel-Velázquez
- Laboratorio de Proteómica e Inmunometabolismo, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (A.T.-G.); (N.B.-H.); (L.S.-d.-P.); (G.E.); (L.A.M.-G.)
| |
Collapse
|
2
|
Serralde-Zuñiga AE, González-Garay AG, Rodríguez-Carmona Y, Meléndez-Mier G. Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review. Obes Facts 2022; 15:473-486. [PMID: 35654016 PMCID: PMC9421708 DOI: 10.1159/000524995] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Accepted: 05/04/2022] [Indexed: 11/28/2022] Open
Abstract
INTRODUCTION Using fluoxetine is one of many weight loss strategies. A serotonin reuptake inhibitor indicated for depression believed to impact weight control by changing an individual's appetite; however, its benefit-risk ratio is unclear. The aim of this review was to assess the efficacy and safety of fluoxetine in reducing weight in adults with overweight or obesity. METHODS We searched Cochrane Library, MEDLINE, Embase, and other databases without language restrictions. Cochrane Collaboration tool and GRADE instrument assessed the risk of bias of randomized controlled trials and certainty of their evidence. We conducted random-effects meta-analyses and calculated the risk ratio/mean difference with 95% confidence intervals for the outcomes. RESULTS We included 19 trials (2,216 adults) and found that fluoxetine may reduce weight by -2.7 kg (95% CI -4 to -1.4; p < 0.001) and body mass index by -1.1 kg/m2 (95% CI -3.7 to 1.4), compared with placebo; however, it would cause approximately twice as many adverse events, such as dizziness, drowsiness, fatigue, insomnia, or nausea. CONCLUSIONS Although low-certainty evidence suggests that off-label fluoxetine may reduce weight, high-certainty research is needed to be conducted in the future to determine its effects exclusively as well as whether it is useful when combined with other agents. This article is based on a Cochrane Review published in the Cochrane Database of Systematic Reviews 2019, Issue 10, DOI: 10.1002/14651858.CD011688.pub2. Cochrane Reviews are regularly updated as new evidence emerges, and in response to feedback, it should be consulted for the most recent version of the review.
Collapse
Affiliation(s)
- Aurora E. Serralde-Zuñiga
- Clinical Nutrition, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
| | | | | | | |
Collapse
|
3
|
Mendoza-Martínez VM, Zavala-Solares MR, Espinosa-Flores AJ, León-Barrera KL, Alcántara-Suárez R, Carrillo-Ruíz JD, Escobedo G, Roldan-Valadez E, Esquivel-Velázquez M, Meléndez-Mier G, Bueno-Hernández N. Is a Non-Caloric Sweetener-Free Diet Good to Treat Functional Gastrointestinal Disorder Symptoms? A Randomized Controlled Trial. Nutrients 2022; 14:nu14051095. [PMID: 35268070 PMCID: PMC8912523 DOI: 10.3390/nu14051095] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 02/28/2022] [Accepted: 03/03/2022] [Indexed: 02/05/2023] Open
Abstract
Background: A diet containing non-caloric sweeteners (NCS) could reduce calorie intake; conversely, some animal studies suggest that NCS consumption may increase functional gastrointestinal disorder symptoms (FGDs). This study aimed to compare the effect of consuming a diet containing NCS (c-NCS) versus a non-caloric sweetener-free diet (NCS-f) on FGDs. Methods: We conducted a randomized, controlled, parallel-group study using two different diets for five weeks: the c-NCS diet contained 50−100 mg/day NCS, whereas the NCS-f diet had less than 10 mg/day NCS. At the beginning of the study (PreTx) and at the end (PostTx), we assessed FGDs, dietary intake, and NCS consumption. Results: The percentage of participants with diarrhea (PreTx = 19% vs. PstTx = 56%; p = 0.02), post-prandial discomfort (PreTx = 9% vs. PstTx = 39%; p = 0.02), constipation (PreTx = 30% vs. PostTx = 56%; p < 0.01), and burning (PreTx = 13% vs. PostTx = 33%; p < 0.01) increased in the c-NCS diet group. Conversely, abdominal pain (PreTx = 15% vs. PostTx = 3%; p = 0.04), post-prandial discomfort (PreTx = 26% vs. PostTx = 6%; p = 0.02), burning (PreTx = 15% vs. PostTx = 0%; p = 0.02), early satiety (PreTx = 18% vs. PostTx = 3%; p < 0.01), and epigastric pain (PreTx = 38% vs. PostTx = 3%; p < 0.01) decreased in the NCS-f diet group. Conclusion: A c-NCS diet is associated with increased FGDs, including diarrhea, post-prandial discomfort, constipation, and burning or retrosternal pain. The NCS-f diet also decreased FGDs, as well as abdominal pain, post-prandial discomfort, burning or retrosternal pain, early satiety, and epigastric pain.
Collapse
Affiliation(s)
- Viridiana Montsserrat Mendoza-Martínez
- Proteomics and Metabolomics Laboratory, Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (V.M.M.-M.); (A.J.E.-F.); (K.L.L.-B.); (M.E.-V.)
| | | | - Aranza Jhosadara Espinosa-Flores
- Proteomics and Metabolomics Laboratory, Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (V.M.M.-M.); (A.J.E.-F.); (K.L.L.-B.); (M.E.-V.)
| | - Karen Lorena León-Barrera
- Proteomics and Metabolomics Laboratory, Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (V.M.M.-M.); (A.J.E.-F.); (K.L.L.-B.); (M.E.-V.)
| | - Raúl Alcántara-Suárez
- Laboratory of Immunometabolism, Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (R.A.-S.); (G.E.)
| | - José Damián Carrillo-Ruíz
- Neurology and Neurosurgery Unit, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico;
- Faculty of Health Sciences, Mexico Anahuac University, Huixquilucan 52786, Mexico
| | - Galileo Escobedo
- Laboratory of Immunometabolism, Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (R.A.-S.); (G.E.)
| | - Ernesto Roldan-Valadez
- Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico;
| | - Marcela Esquivel-Velázquez
- Proteomics and Metabolomics Laboratory, Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (V.M.M.-M.); (A.J.E.-F.); (K.L.L.-B.); (M.E.-V.)
| | - Guillermo Meléndez-Mier
- School of Public Health and Nutrition (FASPyN), Autonomous University of Nuevo Leon, Nuevo Leon 64460, Mexico
- Correspondence: (G.M.-M.); (N.B.-H.)
| | - Nallely Bueno-Hernández
- Proteomics and Metabolomics Laboratory, Research Division, General Hospital of Mexico “Dr. Eduardo Liceaga”, Mexico City 06720, Mexico; (V.M.M.-M.); (A.J.E.-F.); (K.L.L.-B.); (M.E.-V.)
- Correspondence: (G.M.-M.); (N.B.-H.)
| |
Collapse
|
4
|
Bustos-Vázquez E, Padilla-González E, Reyes-Gómez D, Carmona-Ramos MC, Monroy-Vargas JA, Benítez-Herrera AE, Meléndez-Mier G. Survival of COVID-19 with Multimorbidity Patients. Healthcare (Basel) 2021; 9:healthcare9111423. [PMID: 34828470 PMCID: PMC8617866 DOI: 10.3390/healthcare9111423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2021] [Revised: 10/11/2021] [Accepted: 10/14/2021] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND The outbreak of SARS-CoV-2 abruptly disseminated in early 2020, overcoming the capacity of health systems to respond the pandemic. It was not until the vaccines were launched worldwide that an increase in survival was observed. The objectives of this study were to analyse the characteristics of survivors and their relationship with comorbidities. We had access to a database containing information on 16,747 hospitalized patients from Mexico, all infected with SARS-CoV-2, as part of a regular follow-up. The descriptive analysis looked for clusters of either success or failure. We categorized the samples into no comorbidities, or one and up to five coexisting with the infection. We performed a logistic regression test to ascertain what factors were more influential in survival. The main variable of interest was survival associated with multimorbidity factors. The database hosted information on hospitalized patients from Mexico between March 2020 through to April 2021. Categories 2 and 3 had the largest number of patients. Survival rates were higher in categories 0 (64.8%), 1 (57.5%) and 2 (51.6%). In total, 1741 (10.5%) patients were allocated to an ICU unit. Mechanical ventilators were used on 1415 patients, corresponding to 8.76%. Survival was recorded in 9575 patients, accounting for 57.2% of the sample population. Patients without comorbidities, younger people and women were more likely to survive.
Collapse
Affiliation(s)
- E. Bustos-Vázquez
- Department of Epidemiology, Secretary of Health of the State of Hidalgo, Pachuca C.P. 42182, Hidalgo, Mexico; (E.B.-V.); (E.P.-G.); (J.A.M.-V.)
| | - E. Padilla-González
- Department of Epidemiology, Secretary of Health of the State of Hidalgo, Pachuca C.P. 42182, Hidalgo, Mexico; (E.B.-V.); (E.P.-G.); (J.A.M.-V.)
| | - D. Reyes-Gómez
- Public Health Subsecretary of the State of Hidalgo, Pachuca C.P. 42182, Hidalgo, Mexico;
| | - M. C. Carmona-Ramos
- Directorate of Public Health Policies and Strategies, Secretary of Health of the State of Hidalgo, Pachuca C.P. 42182, Hidalgo, Mexico;
| | - J. A. Monroy-Vargas
- Department of Epidemiology, Secretary of Health of the State of Hidalgo, Pachuca C.P. 42182, Hidalgo, Mexico; (E.B.-V.); (E.P.-G.); (J.A.M.-V.)
| | | | - G. Meléndez-Mier
- Health Research Coordination, Secretary of Health of the State of Hidalgo, Pachuca C.P. 42083, Hidalgo, Mexico
- Correspondence: ; Tel.: +52-771-718-0770
| |
Collapse
|
5
|
Cicero-Sabido R, Meléndez-Mier G. The beginnings of tuberculosis pharmacological treatment. GAC MED MEX 2019. [DOI: 10.24875/gmm.m18000199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
6
|
Cicero-Sabido R, Meléndez-Mier G. [Inicio del tratamiento farmacológico de la tuberculosis]. GAC MED MEX 2018; 154:620-621. [PMID: 30407466 DOI: 10.24875/gmm.17003616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The appearance of new anti-tuberculosis drugs such as bedaquiline and delamanid makes it impossible not to remember that the first strictly controlled medical trials of tuberculosis treatment were published in two rigorously researched outstanding articles that can be qualified as historical. In 1948, streptomycin was formally studied as an efficacious anti-tuberculosis drug. In 1952, another trial compared streptomycin-paramino salicylic acid with isoniazid, by means of which the first bases of pharmacological tuberculosis treatment were established.
Collapse
Affiliation(s)
| | - Guillermo Meléndez-Mier
- Secretaría de Salud, Hospital General de México, Dirección de Investigación, Ciudad de México, México
| |
Collapse
|
7
|
Palomera LF, Gómez-Arauz AY, Villanueva-Ortega E, Meléndez-Mier G, Islas-Andrade SA, Escobedo G. Serum levels of interleukin-1 beta associate better with severity of simple steatosis than liver function tests in morbidly obese patients. J Res Med Sci 2018; 23:93. [PMID: 30505331 PMCID: PMC6225445 DOI: 10.4103/jrms.jrms_142_18] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Revised: 05/05/2018] [Accepted: 07/17/2018] [Indexed: 12/21/2022]
Abstract
Background: In high-fat diet-fed mice, interleukin-1 beta (IL-1 beta) has been shown to play a key role in hepatic steatosis. However, it remains unknown whether IL-1 beta could be associated with different grades of steatosis in obese humans. Materials and Methods: Morbidly obese patients (n = 124) aged 18–65 years were divided into four groups: no steatosis (controls), mild steatosis, moderate steatosis, and severe steatosis using abdominal ultrasound. IL-1 beta serum levels and liver function tests were measured and significant differences were estimated by one-way ANOVA followed by Tukey test. Results: IL-1 beta serum levels significantly increased in morbidly obese patients with mild (11.38 ± 2.40 pg/ml), moderate (16.72 ± 2.47 pg/ml), and severe steatosis (23.29 ± 5.2 pg/ml) as compared to controls (7.78 ± 2.26 pg/ml). Liver function tests did not significantly change among different grades of steatosis. Conclusion: IL-1 beta serum levels associate better with steatosis degree than liver function tests in morbidly obese population.
Collapse
Affiliation(s)
- Leon F Palomera
- Research Division, Laboratory for Proteomics and Metabolomics, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
| | - Angélica Y Gómez-Arauz
- Research Division, Laboratory for Proteomics and Metabolomics, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
| | - Eréndira Villanueva-Ortega
- Department of Genetics, Clinic for Obesity, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
| | - Guillermo Meléndez-Mier
- Research Division, Laboratory for Proteomics and Metabolomics, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
| | - Sergio A Islas-Andrade
- Research Division, Laboratory for Proteomics and Metabolomics, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
| | - Galileo Escobedo
- Research Division, Laboratory for Proteomics and Metabolomics, General Hospital of Mexico "Dr. Eduardo Liceaga", Mexico City, Mexico
| |
Collapse
|
8
|
Ramos-Peñafiel C, Olarte-Carrillo I, Cerón-Maldonado R, Rozen-Fuller E, Kassack-Ipiña JJ, Meléndez-Mier G, Collazo-Jaloma J, Martínez-Tovar A. Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene. J Transl Med 2018; 16:245. [PMID: 30176891 PMCID: PMC6122769 DOI: 10.1186/s12967-018-1620-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2018] [Accepted: 08/25/2018] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND In acute lymphoblastic leukemia (ALL), high ABCB1 gene expression has been associated with treatment resistance, which affects patient prognosis. Many preclinical reports and retrospective population studies have shown an anti-cancer effect of metformin. Therefore, the objective of this study was to assess the effect of metformin on the treatment regimen in patients with ALL who exhibited high levels of ABCB1 gene expression and to determine its impact on overall survival. METHODS A total of 102 patients with ALL were recruited; one group (n = 26) received metformin, and the other received chemotherapy (n = 76). Measurement of ABCB1 transcript expression was performed using qRT-PCR prior to treatment initiation. Survival analysis was performed using Kaplan-Meier curves. The impact of both the type of treatment and the level of expression on the response (remission or relapse) was analyzed by calculating the odds ratio. RESULTS The survival of patients with high ABCB1 expression was lower than those with low or absent ABCB1 gene expression (p = 0.030). In the individual analysis, we identified a benefit to adding metformin in the group of patients with high ABCB1 gene expression (p = 0.025). In the metformin user group, the drug acted as a protective factor against both therapeutic failure (odds ratio [OR] 0.07, 95% confidence interval [CI] 0.0037-1.53) and early relapse (OR 0.05, 95% CI 0.0028-1.153). CONCLUSION The combined use of metformin with chemotherapy is effective in patients with elevated levels of ABCB1 gene expression. Trial registration NCT 03118128: NCT.
Collapse
Affiliation(s)
- Christian Ramos-Peñafiel
- Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México
| | - Irma Olarte-Carrillo
- Laboratorio de Biología Molecular, Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México
| | - Rafael Cerón-Maldonado
- Laboratorio de Biología Molecular, Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México
| | - Etta Rozen-Fuller
- Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México
| | - Juan Julio Kassack-Ipiña
- Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México
| | - Guillermo Meléndez-Mier
- Dirección de Investigación, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México
| | - Juan Collazo-Jaloma
- Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México
| | - Adolfo Martínez-Tovar
- Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México. .,Laboratorio de Biología Molecular, Servicio de Hematología, Hospital General de México, "Dr. Eduardo Liceaga", Ciudad de México, México.
| |
Collapse
|
9
|
Solís-Flores L, Acuña-Rojas R, López-Medina L, Meléndez-Mier G. [The counseling of nursing decreases symptomatology and relapses in pediatric patients with allergic rhinitis]. Bol Med Hosp Infant Mex 2017; 74:349-356. [PMID: 29382478 DOI: 10.1016/j.bmhimx.2017.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Revised: 04/13/2017] [Accepted: 05/11/2017] [Indexed: 10/18/2022] Open
Abstract
BACKGROUND Allergic rhinitis (AR) is considered to be a public health problem, therefore it is essential to test health education strategies such as nursing counseling (NC) aimed at population groups such as children with allergic rhinitis and their tutors. This study aimed to measure the health benefits of children with this disease for a year. METHODS Longitudinal, randomized, comparative study with a sample of 100 pediatric patients of both sexes, aged 6 to 12 years, with diagnosis of allergic rhinitis, with counseling (study group) and without counseling (control group). In both groups, an informed consent letter signed by both tutors was obtained, in addition to knowledge and assessment papers; the latter included a scale of symptomatology and Morisky Green (adherence to treatment). The children in the study group received intervention based on personalized education, didactic material, support of the multidisciplinary group if necessary (doctor, dermatologist and psychologist). The control group received usual care. In both groups, telephone follow-up was performed, which allowed the number of relapses to be identified in one year. RESULTS The Wilcoxon rank-sum test (Mann-Whitney) was used to compare the results; the presence of relapses in the control group was statistically significant compared to the study group. CONCLUSIONS It was found that the infant population that receives NC, has as a better benefit the control of the symptomatology and decrease of relapses per year.
Collapse
Affiliation(s)
- Laura Solís-Flores
- Departamento de Educación, Capacitación e Investigación en Enfermería del Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México
| | - Rosalinda Acuña-Rojas
- Servicio de Pediatría del Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México
| | - Leobardo López-Medina
- Unidad 309 de Alergia, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México.
| | - Guillermo Meléndez-Mier
- Departamento de Registro y Seguimiento de proyectos de la Dirección de Investigación del Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México
| |
Collapse
|